Page 144 - NobleCon19revC2_Neat

Health Care
Date November 21, 2023 Health Care
52wk High $1.49
52wk Low $0.55 Onconova Therapeutics, Inc ONTX $0.65
12 Penns Trail
Newtown, PA 18940

(USD - in millions) www.onconova.com
Market Cap 13.8
Enterprise (11.4)
Basic Shares Out. 21.00 COMPANY OVERVIEW
Float 20.85
Institutional Holdings 8.48% Detailed Analysis:Channelchek.com
Short Interest 0.07
Avg. 90-Day Volume 0.07 Onconova Therapeutics is a clinical-stage biopharmaceutical company
focused on discovering and developing novel products for patients with
cancer. The Company has proprietary targeted anti-cancer agents
designed to disrupt specific cellular pathways that are important for
EPS Data cancer cell proliferation. Onconova’s novel, proprietary multi-kinase
inhibitor narazaciclib (formerly ON 123300) is being evaluated in a
2021 2022 2023 combination trial with estrogen blockade in advanced endometrial
CQ1 (0.30) (0.20) (0.28) cancer. Based on preclinical and clinical studies of CDK 4/6 inhibitors,
CQ2 (0.27) (0.19) (0.20) Onconova is also evaluating opportunities for combination studies with
narazaciclib in additional indications.
CQ3 (0.22) (0.26) (0.23)
CQ4 (0.16) (0.26) (0.27)
CY (0.96) (0.91) (0.97) Source: Channelchek/QuoteMedia

Long-Term EPS Estimate N/A
Price/Book (mrq) 0.69
ROE (ttm) -84.30
Debt-to-Total Cap. (mrq) N/A
Fiscal Year End 31-Dec
12 Penns Trai Newtown PA 18940

Key Executives
CEO: Fruchtman, Steven
CFO: Guerin, Mark
COO: Guerin, Mark
IR: N/A
Noble Capital Markets, Inc.
Source: Capital IQ, Noble Financial estimates, company filings
Noble Senior Analyst 561-994-1191 noblecapitalmarkets.com
Robert LeBoyer MEMBERS: FINRA, SIPC, MSRB
Following the conference, complete video library of presentations will be
rleboyer@noblelsp.com available at: channelchek.com | nobleconference.com
(212) 896-4625

Refer to the back of the book for disclosures